Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Amortizatization of Intangibles (2021 - 2025)

Historic Amortizatization of Intangibles for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2025 value amounting to $150175.3.

  • Ascendis Pharma A's Amortizatization of Intangibles rose 1809.68% to $150175.3 in Q4 2025 from the same period last year, while for Dec 2025 it was $553846.5, marking a year-over-year increase of 956.61%. This contributed to the annual value of $553750.1 for FY2025, which is 1096.44% up from last year.
  • Per Ascendis Pharma A's latest filing, its Amortizatization of Intangibles stood at $150175.3 for Q4 2025, which was up 1809.68% from $143793.8 recorded in Q3 2025.
  • Ascendis Pharma A's Amortizatization of Intangibles' 5-year high stood at $161391.0 during Q4 2023, with a 5-year trough of $111918.5 in Q3 2022.
  • For the 5-year period, Ascendis Pharma A's Amortizatization of Intangibles averaged around $128817.7, with its median value being $126729.0 (2024).
  • In the last 5 years, Ascendis Pharma A's Amortizatization of Intangibles soared by 4251.18% in 2023 and then tumbled by 2120.82% in 2024.
  • Ascendis Pharma A's Amortizatization of Intangibles (Quarter) stood at $128124.8 in 2021, then dropped by 11.61% to $113247.5 in 2022, then soared by 42.51% to $161391.0 in 2023, then decreased by 21.21% to $127162.8 in 2024, then grew by 18.1% to $150175.3 in 2025.
  • Its Amortizatization of Intangibles stands at $150175.3 for Q4 2025, versus $143793.8 for Q3 2025 and $134703.2 for Q2 2025.